Literature DB >> 15248383

Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure.

E Kayacetin1, S Köklü, T Temuçin.   

Abstract

Autoimmune hepatitis and primary biliary cirrhosis are generally easy to discriminate on the basis of clinical, laboratory, and histological findings. The presence of anti-mitocondrial antibodies seropositivity and cholestatic clinical, laboratory, and/or histological features in patients with autoimmune hepatitis indicates the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis. Fulminant hepatic failure is an unusual initial form of presentation of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. We report the case of a 50-year-old woman with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome who presented with fulminant hepatic failure. Fulminant hepatic failure has a high mortality rate and may require liver transplant. Our patient revealed a good response to corticosteroid and ursodeoxycholic acid therapy. It is important to identify and distinguish autoimmune hepatitis and variant syndromes from other forms of liver disease because of response to corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248383     DOI: 10.1016/j.dld.2003.09.023

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Concurrent primary biliary cirrhosis and autoimmune hepatitis presenting as subfulminant hepatic failure.

Authors:  Jason Ken Hou; M Eric Gershwin; Linda K Green; Boris Yoffe
Journal:  BMJ Case Rep       Date:  2009-03-17

Review 2.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 3.  Overlap syndromes: an emerging diagnostic and therapeutic challenge.

Authors:  Pooja Dhiman; Sharad Malhotra
Journal:  Saudi J Gastroenterol       Date:  2014 Nov-Dec       Impact factor: 2.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.